id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-035333-2duu1c9n	MacLaren, Graeme	What’s new in ECMO for COVID-19?	2020-11-12		.txt	text/plain	1411	73	46	The first studies of coronavirus disease 2019 (COVID-19) from China reported high mortality rates in patients supported with extracorporeal membrane oxygenation (ECMO) [1]. Eightythree (17%) of 492 intensive care patients with COVID-19-related acute respiratory distress syndrome (ARDS) received ECMO and were ultimately assessed to have an estimated probability of 60-day mortality of 31% (95% CI 22-42). This report provided insights into the use of ECMO for COVID-19 in experienced centres, including those which had participated in the EOLIA trial, and had consistent protocols and standardized ARDS management practices in place prior to the pandemic. There is greater uncertainty about the role of ECMO in other populations with COVID-19, such as patients requiring mechanical circulatory support, extracorporeal cardiopulmonary resuscitation (ECPR) [14] , or those with multisystem inflammatory syndrome in children. What is required now are data concerning long-term morbidity and mortality, and whether any practices-including prone positioning, optimal anticoagulation, early extubation and use of mechanical right ventricular support-during ECMO can improve these outcomes.	./cache/cord-035333-2duu1c9n.txt	./txt/cord-035333-2duu1c9n.txt